Frank S. Czerwiec

7.8k total citations · 3 hit papers
63 papers, 5.6k citations indexed

About

Frank S. Czerwiec is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frank S. Czerwiec has authored 63 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 23 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frank S. Czerwiec's work include Genetic and Kidney Cyst Diseases (32 papers), Electrolyte and hormonal disorders (13 papers) and Ion Transport and Channel Regulation (10 papers). Frank S. Czerwiec is often cited by papers focused on Genetic and Kidney Cyst Diseases (32 papers), Electrolyte and hormonal disorders (13 papers) and Ion Transport and Channel Regulation (10 papers). Frank S. Czerwiec collaborates with scholars based in United States, Netherlands and Switzerland. Frank S. Czerwiec's co-authors include John Ouyang, Vicente E. Torres, Arlene B. Chapman, Ronald D. Perrone, Olivier Devuyst, Holly B. Krasa, Ron T. Gansevoort, Cesare Orlandi, Joseph G. Verbalis and Robert W. Schrier and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Frank S. Czerwiec

62 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

2012 1.1k citations Vicente E. Torres, Arlene B. Chapman et al. New England Journal of Medicine profile →
Tolvaptan, a Selective Oral Vasopressin V ₂ -Receptor Antagonist, for Hyponatremia

2006 815 citations Robert W. Schrier, Peter Groß et al. New England Journal of Medicine profile →
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

2017 398 citations Vicente E. Torres, Arlene B. Chapman et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank S. Czerwiec United States	33	2.6k	2.5k	2.3k	978	926	63	5.6k
Arlene B. Chapman United States	52	8.6k 3.2×	5.3k 2.1×	1.7k 0.7×	2.6k 2.6×	2.1k 2.3×	138	10.3k
Marcus Quinkler Germany	54	534 0.2×	1.6k 0.6×	597 0.3×	397 0.4×	252 0.3×	250	9.3k
Takao Sugiyama Japan	35	495 0.2×	1.5k 0.6×	648 0.3×	164 0.2×	271 0.3×	163	5.1k
Frederick C. Goetz United States	36	1.5k 0.6×	650 0.3×	284 0.1×	933 1.0×	141 0.2×	108	6.3k
Rudolf W. Bilous United Kingdom	22	643 0.2×	1.0k 0.4×	341 0.1×	1.9k 1.9×	195 0.2×	36	4.1k
Hans J. Arnqvist Sweden	45	1.9k 0.7×	1.2k 0.5×	161 0.1×	537 0.5×	326 0.4×	167	5.7k
Minoru Kihara Japan	49	902 0.3×	1.5k 0.6×	560 0.2×	274 0.3×	373 0.4×	248	9.3k
Mónica Rupérez Spain	27	243 0.1×	1.4k 0.6×	407 0.2×	581 0.6×	221 0.2×	29	4.0k
Iris Z. Jaffe United States	43	395 0.1×	1.1k 0.5×	551 0.2×	157 0.2×	151 0.2×	115	5.3k
Almut Grenz Germany	29	163 0.1×	918 0.4×	405 0.2×	358 0.4×	412 0.4×	50	3.6k

Countries citing papers authored by Frank S. Czerwiec

Since Specialization

Citations

This map shows the geographic impact of Frank S. Czerwiec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank S. Czerwiec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank S. Czerwiec more than expected).

Fields of papers citing papers by Frank S. Czerwiec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank S. Czerwiec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank S. Czerwiec. The network helps show where Frank S. Czerwiec may publish in the future.

Co-authorship network of co-authors of Frank S. Czerwiec

This figure shows the co-authorship network connecting the top 25 collaborators of Frank S. Czerwiec. A scholar is included among the top collaborators of Frank S. Czerwiec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank S. Czerwiec. Frank S. Czerwiec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adams, Annette L., Iris Reyes, Richard Contreras, et al.. (2025). Fracture risk by cortisol excess status in patients with adrenal incidentalomas: a population-based cohort study. JBMR Plus. 9(5). ziaf043–ziaf043. 1 indexed citations

Chen, Wansu, Richard Contreras, Iris Reyes, et al.. (2023). Dexamethasone Suppression Testing in a Contemporary Cohort with Adrenal Incidentalomas in Two U.S. Integrated Healthcare Systems. Biomedicines. 11(12). 3167–3167. 1 indexed citations

Gansevoort, Ron T., Maatje D.A. van Gastel, Arlene B. Chapman, et al.. (2019). Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney International. 96(1). 159–169. 54 indexed citations

Edwards, Marie E., Fouad T. Chebib, María V. Irazabal, et al.. (2018). Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology. 13(8). 1153–1161. 58 indexed citations

Perrone, Ronald D., Samer Mouksassi, Klaus Romero, et al.. (2017). Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports. 2(3). 442–450. 91 indexed citations

Perrone, Ronald D., Samer Mouksassi, Klaus Romero, et al.. (2017). A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports. 2(3). 451–460. 18 indexed citations

Torres, Vicente E., Olivier Devuyst, Arlene B. Chapman, et al.. (2017). Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology. 45(3). 257–266. 18 indexed citations

Kline, Timothy L., Panagiotis Korfiatis, Marie E. Edwards, et al.. (2017). Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys. Journal of Digital Imaging. 30(4). 442–448. 108 indexed citations

Devuyst, Olivier, Arlene B. Chapman, Ron T. Gansevoort, et al.. (2016). Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology. 28(5). 1592–1602. 65 indexed citations

10.

Casteleijn, Niek F., Jaime D. Blais, Arlene B. Chapman, et al.. (2016). Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. American Journal of Kidney Diseases. 69(2). 210–219. 29 indexed citations

11.

Verbalis, Joseph G., Howard Ellison, Mary Hobart, et al.. (2016). Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT). American Journal of Kidney Diseases. 67(6). 893–901. 42 indexed citations

12.

Boertien, Wendy E., Esther Meijer, Paul E. de Jong, et al.. (2015). Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. American Journal of Kidney Diseases. 65(6). 833–841. 66 indexed citations

13.

Gansevoort, Ron T., Esther Meijer, Arlene B. Chapman, et al.. (2015). Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology Dialysis Transplantation. 31(11). 1887–1894. 44 indexed citations

14.

Perrone, Ronald D., Jon Neville, Arlene B. Chapman, et al.. (2015). Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases. 66(4). 583–590. 19 indexed citations

15.

Irazabal, María V., Vicente E. Torres, Marie C. Hogan, et al.. (2011). Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney International. 80(3). 295–301. 101 indexed citations

16.

Verbalis, Joseph G., et al.. (2011). Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology. 164(5). 725–732. 133 indexed citations

17.

McInnis, Melvin G., et al.. (2009). PSY37 IMPACT OF TOLVAPTAN ON SELF-REPORTED UTILITY SCORES IN HYPONATREMIC PATIENTS. Value in Health. 12(7). A382–A382. 1 indexed citations

18.

Schrier, Robert W., Peter Groß, Mihai Gheorghiade, et al.. (2006). Tolvaptan, a Selective Oral Vasopressin V ₂ -Receptor Antagonist, for Hyponatremia. New England Journal of Medicine. 355(20). 2099–2112. 815 indexed citations breakdown →

19.

Chen, Clara C., Frank S. Czerwiec, & Penelope Feuillan. (1998). Visualization of fibrous dysplasia during somatostatin receptor scintigraphy.. PubMed. 39(2). 238–40. 18 indexed citations

20.

Czerwiec, Frank S., Michael H. Melner, & David Puett. (1989). Transiently Elevated Levels of c-fosand c-mycOncogene Messenger Ribonucleic Acids in Cultured Murine Leydig Tumor Cells after Addition of Human Chorionic Gonadotropin. Molecular Endocrinology. 3(1). 105–109. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact